ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

TBIO Telesis Bio Inc

0.33
0.00 (0.00%)
05 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Telesis Bio Inc TBIO NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.00 0.00% 0.33 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
0.33
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
18/4/202408:00GLOBETelesis Bio Inc. announces strategic focus on game-changing..
28/3/202415:05GLOBETelesis Bio Reports Fourth Quarter and Full Year 2023..
05/3/202417:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202417:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202417:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202419:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202419:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/2/202416:00EDGAR2Form 8-K - Current report
26/2/202408:15GLOBETelesis Bio Announces Select Preliminary Fourth Quarter..
30/11/202316:00EDGAR2Form 8-K - Current report
13/11/202315:32EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/11/202315:32EDGAR2Form 8-K - Current report
13/11/202315:22GLOBETelesis Bio Reports Third Quarter 2023 Financial Results
09/11/202316:00EDGAR2Form 8-K - Current report
07/11/202308:00GLOBETelesis Bio to Report Third Quarter Financial Results on..
03/11/202311:00GLOBETelesis Bio Announces Commercial Release of Cell-free..
24/10/202315:30EDGAR2Form 8-K - Current report
28/9/202314:48GLOBETelesis Bio Announces Commercial Release of BioXp® NGS..
22/9/202316:00EDGAR2Form 8-K - Current report
29/8/202315:05GLOBETelesis Bio Appoints William J. Kullback Chief Financial..
29/8/202315:02EDGAR2Form 8-K - Current report
11/8/202305:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202315:17EDGAR2Form 8-K - Current report
10/8/202315:05GLOBETelesis Bio Reports Second Quarter 2023 Financial Results
03/8/202323:15EDGAR2Form EFFECT - Notice of Effectiveness
03/8/202316:00GLOBETelesis Bio to Report Second Quarter Financial Results on..
27/7/202316:28EDGAR2Form S-3 - Registration statement under Securities Act of..
07/7/202315:01EDGAR2Form 8-K - Current report
08/6/202308:05GLOBETelesis Bio to Present at Jefferies Healthcare Conference..
06/6/202302:00GLOBETelesis Bio to Present at Antibody Engineering and..
05/6/202316:30GLOBETelesis Bio Announces Closing of $28.0 Million Private..
31/5/202316:29GLOBETelesis Bio Secures Financing of $28.0 Million
23/5/202308:00GLOBETelesis Bio to Present at SynBioBeta 2023
22/5/202311:00GLOBETelesis Bio Announces First Commercial Shipment of BioXp®..
18/5/202309:00GLOBETelesis Bio Announces First Commercial Shipment of BioXp®..
15/5/202308:00GLOBETelesis Bio to Present at Protein Engineering Summit (PEGS..
11/5/202315:05GLOBETelesis Bio Reports First Quarter 2023 Financial Results

Su Consulta Reciente

Delayed Upgrade Clock